Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1989-2000

  Uzgare, Rajneesh P ^a   Sheets, Timothy P ^a   Johnston, Daniel S ^a  

^a Delcath Systems Inc   (United States)

Author keywords

Chemosaturation therapy; Melphalan; Percutaneous hepatic perfusion; Platinum agents; Taxanes

Indexed keywords

ANTIINFECTIVE AGENT; CYTOTOXIC AGENT; MELPHALAN; OXALIPLATIN; PACLITAXEL;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLON CANCER; DRUG EXPOSURE; DRUG SCREENING; HEPATIC ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; LIVER CELL; LIVER PERFUSION; PERCUTANEOUS HEPATIC PERFUSION; PRIORITY JOURNAL; STOMACH CANCER;

CHEMOSATURATION THERAPY; MELPHALAN; PERCUTANEOUS HEPATIC PERFUSION; PLATINUM AGENTS; TAXANES;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; COLONIC NEOPLASMS; FLOW CYTOMETRY; HEPATIC ARTERY; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MELPHALAN; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PERFUSION; STOMACH NEOPLASMS;

EID: 84878167252     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Souliotis VL, Dimopoulos MA and Sfikakis PP: Gene-specific formation and repair of DNA monoadducts and interstrand crosslinks after therapeutic exposure to nitrogen mustards. Clin Cancer Res 9: 4465-4474, 2003. (Pubitemid 37248405)
2. Fu D, Calvo JA and Samson LD: Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 12: 104-120, 2012.
3. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D and Hartley JA: Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100: 224-229, 2002. (Pubitemid 35177451)
4. Krause C, Kluttermann K and Mauz-Korholz C: Molecular mechanisms and gene regulation of melphalan- and hyperthermia-induced apoptosis in Ewing sarcoma cells. Anticancer Res 28:2585-2593, 2008.
5. Kresse M, Latta M, Kunstle G, Riehle HM, van Rooijen N, Hentze H, Tiegs G, Biburger M, Lucas R and Wendel A: Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. J Immunol 175: 4076-4083, 2005. (Pubitemid 41292071)
6. Fojo T and Menefee M: Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol 18(Suppl 5): v3-8, 2007.
7. Perez EA: Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8: 2086-2095, 2009.
8. Rodriguez-Antona C: Pharmacogenomics of paclitaxel. Pharmacogenomics 11: 621-623, 2010.
9. Todd RC and Lippard SJ: Inhibition of transcription by platinum antitumor compounds. Metallomics 1: 280-291, 2009.
10. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L and Saif MW: Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010.
11. Wang Y, Probin V and Zhou D: Cancer therapy-induced residual bone marrow injury: Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev 2: 271-279, 2006. (Pubitemid 44203363)
12. van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA and van de Velde CJ: Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 15: 1891-1898, 2008.
13. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL and Bachenheimer LC: A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6: 3062-3070, 2000. (Pubitemid 30637729)
14. Alexander HR Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C and Beresneva T: Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9: 6343-6349, 2003. (Pubitemid 38031818)
15. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD and Alexander HR: Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23: 3465-3474, 2005.
16. Pingpank JF, S. HM, Faries MB, Zager JS, Alexander HR and Royal R: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastaticocular or cutaneous melanoma {abstract}. J Clin Oncol 28: 18s, 2010.
17. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD and Thirlwell MP: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17: 3403-3411, 1999. (Pubitemid 29517907)
18. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V and Crown J: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581, 1995.
19. Extra JM, Espie M, Calvo F, Ferme C, Mignot L and Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303, 1990. (Pubitemid 20014976)
20. Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G and Homerin M: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9:105-108, 1998. (Pubitemid 28125772)
21. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH and Kurzrock R: A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 116: 4086-4094, 2010.
22. Lee JL, Gooley T, Bensinger W, Schiffman K and McDonald GB: Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 5: 306-315, 1999.
23. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM and Ivy P: Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: A National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13: 3660-3666, 2007. (Pubitemid 46955130)
24. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM and Beijnen JH: Taxanes: A new class of antitumor agents. Cancer Invest 13:381-404, 1995.
25. Kornmann M, Fakler H, Butzer U, Beger HG and Link KH: Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 20: 3259-3264, 2000.
26. Boulin M, Guiu S, Chauffert B, Aho S, Cercueil JP, Ghiringhelli F, Krause D, Fagnoni P, Hillon P, Bedenne L and Guiu B: Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs 22: 741-748, 2011.
27. van Iersel LB, Koudijs TM, Hoekman EJ, Janssen-van Rhijn CM, Vahrmeijer AL, Nortier JW, van de Velde CJ, Gelderblom H and Kuppen PJ: In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines. J Surg Res 167: 273-278, 2011.
28. Kuhn JA, McLoughlin JM, Harris DC, Talaasen LJ, Sutton SW and McCarty TM: Intraperitoneal hyperthermic chemotherapy: Experience at Baylor University Medical Center. Proc Bayl Univ Med Cent 15: 359-362, 2002.
29. Pohlen U, Rieger H, Kunick-Pohlen S, Berger G and Buhr HJ: Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res 27: 667-674, 2007. (Pubitemid 46374992)
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
31. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB: Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL-positive cells. Nat Med 2: 561-566, 1996.
32. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932, 2000. (Pubitemid 30618049)
33. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U and Benes CH: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575, 2012.
34. Gerson SL, Bhalla KN, Grant S, Natarajan K, Creger RJ and DeRemer DL: Pharmacology and molecular mechanism of antineoplastic agents for hematologic malignancies. In:Hematology: Basic Principles and Practice. Hoffman R. (ed.). New York: Churchill Livingstone, 2009.
35. Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, Yamamoto K, Yamamoto S, Kudo Y, Mohri D, Isomura Y, Ijichi H, Tateishi K, Kanai F, Ogawa S, Omata M and Koike K: Gastric cancer cell line Hs746T harbors a splice site mutation of c-MET causing juxtamembrane domain deletion. Biochem Biophys Res Commun 394: 1042-1046, 2010.